Please assess the completion status of the following clinical trial:

Trial Title: Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for bipolar I disorder without psychotic features confirmed by the administration of the Mini International Neuropsychiatric Interview (MINI), with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration~* Currently treated as an outpatient at the time of enrollment~* A verified previous manic or mixed episode. Verification must include one of the following sources: --Treatment of mania with an anti-manic agent (eg, lithium or divalproate) or antipsychotic medication with an approved indication for mania --Hospital records/Medical records --Participant report corroborated by caretaker or previous or current treating clinician~* 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≥ 20~* HAMD-17 item 1 score ≥ 2~* Clinical Global Impressions-Severity (CGI-S) score ≥ 4~* Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test (women of childbearing potential only)~* Normal physical examination, clinical laboratory test results, and electrocardiogram (ECG) results or abnormal findings that are judged not clinically significant by the Principal Investigator (PI)~Exclusion Criteria:~* Young Mania Rating Scale (YMRS) total score \> 12~* Four or more episodes of a mood disturbance (depression, mania, hypomania, or mixed state) within the 12 months before Visit 1~* Any current axis 1 psychiatric diagnosis other than bipolar disorder with the exception of specific phobias~* History of meeting DSM-5 criteria for: ○ Dementia, amnesic, or other cognitive disorder ○ Schizophrenia, schizoaffective, or other psychotic disorder~  ○ Mental retardation - DSM-5-based diagnosis of borderline or antisocial personality disorder or other axis II disorder of sufficient severity to interfere with participation in this study~* History of meeting DSM-5 criteria for alcohol or substance abuse or dependence (other than nicotine or caffeine) within the 6 months before Visit 1~* Positive result on blood alcohol test or urine drug screen for any prohibited medication. Exception: ○ Participants with a positive cannabinoid on entry may be retested before randomization. If the participant remains positive, the participant is no longer eligible ○ Participants positive for opiates on entry, discussion with Study Physician is required.~* Electroconvulsive therapy in the 3 months before Visit 1~* Previous lack of response to electroconvulsive therapy~* Treatment with a depot antipsychotic drug within 1 treatment cycle before Visit 1~* Treatment with clozapine in a dose of \> 50 mg/day in the past 2 years~* Prior participation in any investigational study of RGH-188 or cariprazine within the past 12 months~* Previous treatment with vagus nerve stimulation or transcranial magnetic stimulation within 6 months before Visit 1~* Prior participation with any clinical trials, involving experimental or investigational drugs, within 6 months before Visit 1 or during the study~* Initiation or termination of psychotherapy for depression within the 3 months preceding Visit 1, or plans to initiate, terminate, or change such therapy during the course of the study.~* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study~* Gastric bypass or any condition that would be expected to affect drug absorption (lap band procedures are acceptable if there is no problem with absorption)~* Known history of cataracts or retinal detachment~* Known human immunodeficiency virus infection~* Employee, or immediate relative of an employee, of the Sponsor, any of its affiliates or partners, or the study center

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
- Cariprazine 1.5 mg (Type: EXPERIMENTAL): Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
- Cariprazine 3.0 mg (Type: EXPERIMENTAL): Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).